• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pharmacokinetics and metabolism of ftorafur in man.

作者信息

Au J L, Wu A T, Friedman M A, Sadée W

出版信息

Cancer Treat Rep. 1979 Mar;63(3):343-50.

PMID:371796
Abstract
摘要

相似文献

1
Pharmacokinetics and metabolism of ftorafur in man.氟尿嘧啶在人体内的药代动力学与代谢
Cancer Treat Rep. 1979 Mar;63(3):343-50.
2
Stereoselective metabolism of ftorafur (R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil).呋喃氟尿嘧啶（R,S-1-(四氢-2-呋喃基)-5-氟尿嘧啶）的立体选择性代谢
Cancer Chemother Pharmacol. 1981;7(1):55-9. doi: 10.1007/BF00258214.
3
[Enzymatic conversion of tegafur in human tumor tissue].
Gan To Kagaku Ryoho. 1983 Jun;10(6):1511-7.
4
[Biotransformation of ftorafur].[呋喃氟尿嘧啶的生物转化]
Vopr Med Khim. 1981 Mar-Apr;27(2):243-7.
5
Metabolic activation of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) to 5-fluorouracil by soluble enzymes.R,S-1-(四氢-2-呋喃基)-5-氟尿嘧啶（替加氟）通过可溶性酶代谢活化为5-氟尿嘧啶。
Cancer Res. 1983 Sep;43(9):4039-44.
6
Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver.微粒体细胞色素P450和胞质胸苷磷酸化酶参与人体肝脏中替加氟生成5-氟尿嘧啶的过程。
Clin Cancer Res. 2001 Mar;7(3):675-81.
7
Activation of Ftorafue [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil] to 5-fluorouracil and gamma-butyrolactone.
Cancer Res. 1980 Aug;40(8 Pt 1):2814-9.
8
Biochemical basis for the differential sensitivity of human T- and B-lymphocyte lines to 5-fluorouracil.人类T淋巴细胞系和B淋巴细胞系对5-氟尿嘧啶敏感性差异的生化基础
Cancer Res. 1982 Sep;42(9):3753-60.
9
Metabolic activation of ftorafur [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil]: the microsomal oxidative pathway.
Biochem Pharmacol. 1982 Sep 15;31(18):3006-8. doi: 10.1016/0006-2952(82)90279-9.
10
Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans.
Cancer Res. 1978 Nov;38(11 Pt 1):3867-70.

引用本文的文献

1
Emerging role of S-1 in gastric cancer.S-1在胃癌中的新作用。
Indian J Med Paediatr Oncol. 2015 Oct-Dec;36(4):219-28. doi: 10.4103/0971-5851.171542.
2
Tegafur and 5-fluorouracil pelvic tissue concentrations in rectal cancer patients receiving preoperative chemoradiation.
Clin Transl Oncol. 2006 Jul;8(7):500-7. doi: 10.1007/s12094-006-0050-8.
3
Stereoselective metabolism of ftorafur (R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil).呋喃氟尿嘧啶（R,S-1-(四氢-2-呋喃基)-5-氟尿嘧啶）的立体选择性代谢
Cancer Chemother Pharmacol. 1981;7(1):55-9. doi: 10.1007/BF00258214.
4
Changes in toxic and antitumor properties of ftorafur by induction or inhibition of the microsomal enzymes activity.
Cancer Chemother Pharmacol. 1981;6(2):183-7. doi: 10.1007/BF00262340.
5
Pharmacokinetics of ftorafur after intravenous and oral administration.
Cancer Chemother Pharmacol. 1983;10(3):150-3. doi: 10.1007/BF00255750.
6
Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with L-cystine.替加氟与L-胱氨酸联合使用对实体腺癌755化疗作用的增强
J Cancer Res Clin Oncol. 1986;111(3):187-90. doi: 10.1007/BF00389232.
7
Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma.
Gastroenterol Jpn. 1987 Feb;22(1):55-62. doi: 10.1007/BF02806335.
8
Phase II trial of UFT in advanced colorectal and gastric cancer.优福定（UFT）用于晚期结直肠癌和胃癌的II期试验。
Br J Cancer. 1990 Dec;62(6):1023-5. doi: 10.1038/bjc.1990.431.
9
Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study.口服替加氟治疗胃肠道癌症：一项II期研究。
Br J Cancer. 1990 Mar;61(3):475-8. doi: 10.1038/bjc.1990.105.
10
Measurement of in vitro cellular pharmacokinetics of 5-fluorouracil in human and rat cancer cell lines and rat hepatocytes using a flow-through system.使用流通系统测定5-氟尿嘧啶在人源和大鼠癌细胞系以及大鼠肝细胞中的体外细胞药代动力学。
Cancer Chemother Pharmacol. 1991;27(4):320-5. doi: 10.1007/BF00685119.